REALVNC
9.6.2022 15:02:03 CEST | Business Wire | Press release
VNC Connect by RealVNC, the remote access service used by hundreds of millions of people worldwide, was audited by Cure53 , the Berlin, Germany-based IT security consultancy who have also audited other industry leading software such as Mozilla VPN, 1Password and Bitwarden. The comprehensive audit, which took 86 person days and included VNC Server and VNC Viewer on Linux, Windows and Mac, VNC Viewer for iOS and Android, the VNC Connect management portal and backend services, found 38 security-relevant discoveries, none of which were critical and only three were deemed high severity, and these were fixed immediately. The report states, in conclusion, that RealVNC places a strong focus on the security posture of all its components.
“As the technologists responsible for bringing remote access to the mass market, we are today setting new standards and expectations for security in the face of the challenges of the modern IT environment. IT buyers of remote access technologies should expect no less than independent and comprehensive third-party validation of vendor claims. This is especially true for remote access software where the stakes are high, and a mistake could be reputationally damaging or even existential. With Cure53’s report, buyers can be confident that choosing RealVNC as their remote access vendor will never be a regret,” said Adam Greenwood-Byrne, CEO of RealVNC.
A white box security audit is significantly more in-depth than the more common black box penetration test (which RealVNC also commissions by an external organization annually), as the auditors have access to all of the source code, binaries and API/protocol documentation. Of the 38 vulnerabilities found across the range of software and services tested, 32 have been properly addressed — with the fixes confirmed by Cure53 — while the other six were flagged as either false-alerts or works-as-intended and evaluated to be of lower risk.
“At RealVNC, we operate from the standpoint that no company should ever take a vendor’s word for it when they claim their software is secure, which is why we chose to complete a white box audit with a highly regarded security consultancy to prove it,” said Andrew Woodhouse, CIO of RealVNC.
The Cure53 team is highly motivated to find issues when completing white box penetration tests. The fact that no critical threats were found reinforces RealVNC’s focus on ensuring its customers remain safe from threats when using VNC Connect.
“Cure53 is happy to state that test preparation, test execution and also the fix verification, which is one of the most important parts of such an audit, went smoothly and professionally. It is clear that RealVNC has demonstrated a genuine interest in ensuring VNC Connect's security and is prepared and committed to maintaining the high standards we have observed,” said Dr.-Ing. Mario Heiderich, Founder of Cure53.
Headquartered in Cambridge, RealVNC's products for desktop, mobile and embedded platforms make it easy for users to access and operate devices remotely while enabling remote users to work with technicians to resolve problems easily.
“We’re not shying away from any of the issues the report found. We actively fixed issues as they came up and, as security is an ever changing landscape, we’ll continue to ensure the security of VNC Connect in future iterations of the service,” said Ben May, Head of Cyber Security at RealVNC.
To review Cure53's summary of the audit, click here , and to learn more about why RealVNC chose to conduct a Cure53 audit, click here .
ABOUT REALVNC
RealVNC’s secure remote access and management software is used by hundreds of millions of people worldwide. Their software helps organizations cut costs and improve the quality of supporting remote devices and applications, as well as enabling remote working. RealVNC is the original, UK-based, inventor of VNC remote access software and they support an unrivaled mix of desktop, mobile and embedded platforms.
ABOUT CURE53
Cure53 offers classic black-box penetration tests (zero-knowledge) as well as white-box tests and code audits. Web application and mobile app developers speak many languages and so do we. From classic languages such as PHP, JavaScript, ActionScript, Java, Ruby, Python and Perl to more exotic candidates like web back-ends written in C++ and Delphi – we've seen them.
Since Cure53 was founded in 2007, we have performed hundreds of penetration tests against all kinds of web applications, online services, hardware interfaces, mobile applications, libraries and crypto tools. We value manual and thorough tests, human interaction and communication and a short yet-to-the-point penetration test report without overhead or pie charts no one wants to see.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
